Drug Profile
GW 471552
Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Mycoses; Pneumocystis pneumonia
Most Recent Events
- 02 Oct 2006 Discontinued - Preclinical for Mycoses in Spain (unspecified route)
- 02 Oct 2006 Discontinued - Preclinical for Pneumocystis pneumonia in Spain (unspecified route)
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline